Corium’s clinical-stage MicroCor platform delivers drugs using an integrated transdermal system in a one-step and user-friendly process. The system integrates drug molecules directly into arrays of solid-state biodegradable microstructures, or “microneedles”, which penetrate the outer layers of the skin to release the drug for local or systemic absorption. There are no sharps left behind after use, providing a safer delivery system. The solid-state nature of MicroCor TDS allows room temperature stability, simplifying handling, storage and reducing wastage. MicroCor platform allows larger molecules, such as peptides, proteins and vaccines, to be delivered efficiently and effectively through the skin and also provides for faster skin permeation of molecules. Corium has GMP manufacturing facilities and has developed a cost-effective manufacturing process. Preclinical and clinical data with various peptides will be presented.
Dr. Singh is the Chief Technology Officer and Vice President, Research and Development at Corium. He has over 20 years experience in the pharmaceutical and drug delivery industry. He has held R&D and senior management positions at Ciba-Geigy, Novartis, Vyteris and Corium. He has led the development of several novel passive and active transdermal technology platforms, which resulted in commercialization of a number of transdermal and oral healthcare products. Dr. Singh has over 40 publications in peer reviewed journals and over 25 issued and pending patents. He received his Ph.D. in Pharmaceutics from the University of Queensland, Australia and a Post-Doctoral fellowship from the University of California at San Francisco. He is a member of the American Association of Pharmaceutical Scientists and the Controlled Release Society.